# US 2021/0069252 A1 · Use of pharmaceutical composition in preparing drug for treating pancreas damage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069252 A1
- Document ID: US20210069252A1
- Status: Published application
- Kind: A1
- Application number: 16/757,763
- Filed: 2017-11-03
- Published: 2021-03-11
- Earliest claimed: 2017-11-03
- Assignees: Numen Biotech Co., Ltd
- Applicants: Numen Biotech Co., Ltd
- Inventors: SHAW-YIH LIOU; CHIH-YANG HUANG; TSAI-JUI LIOU; TUNG-SHENG CHEN; I-TE LIOU
- Web page: https://patentgrep.com/patent/US20210069252A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 35/35: Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A use of a pharmaceutical composition in preparing a drug for treating pancreas damage. The pharmaceutical composition comprises pretreated adipose-derived stem cells and ester-type catechin, wherein the pretreated adipose-derived stem cells are obtained by co-culturing ester-type catechin with adipose-derived stem cells.

## Claims

### Claim 1

A use of a pharmaceutical composition in preparing a drug for treating pancreas damage, characterized in that the pharmaceutical composition comprising a plurality of pretreated adipose-derived stem cells and an ester type catechin, wherein the plurality of pretreated adipose-derived stem cells are cultured with the ester type catechin.

### Claim 2 (depends on 1)

The use of claim 1, characterized in that the damaged pancreas cause diabetes or hyperglycemia.

### Claim 3 (depends on 1)

The use of claim 1, characterized in that the damaged pancreas is a plurality of damaged beta cells.

### Claim 4 (depends on 1)

The use of claim 1, characterized in that the pretreated adipose-derived stem cells are pretreated with the ester type catechin for 2 hours.

### Claim 5 (depends on 1)

The use of claim 1, characterized in that the concentration of ester type catechin for the pretreated adipose-derived stem cells is 5-25 μM.

### Claim 6 (depends on 1)

The use of claim 1, characterized in that the concentration of ester type catechin for the pretreated adipose-derived stem cells is lower than 20 μM.

### Claim 7 (depends on 1)

The use of claim 1, characterized in that the pretreated adipose-derived stem cells have higher viability than the not-pretreated adipose-derived stem cells in a high glucose environment, wherein the high glucose environment means the glucose concentration is 22 mM-44 mM, mainly 33 mM, the high viability is 80%-100%.

### Claim 8 (depends on 1)

The use of claim 1, characterized in that the pretreated adipose-derived stem cells increase expression level of a group of survival related protein in the damaged pancreas compared with the not-pretreated adipose-derived stem cells, wherein the group of survival related protein comprising p-IGF1R, P13K, p-PI3K, Akt, p-Akt, p-Bad and Bcl-xL, the percentage of increase is 50%˜100%.

### Claim 9 (depends on 1)

The use of claim 1, characterized in that the pretreated adipose-derived stem cells increase expression level of a group of Sirt1 pathway related protein in the damaged pancreas compared with the not-pretreated adipose-derived stem cells, wherein the group of Sirt1 pathway related protein comprises p-AMPK and Sirt1, the percentage of increase is 50%˜100%.

### Claim 10 (depends on 1)

The use of claim 1, characterized in that the pretreated adipose-derived stem cells reduce expression level of a group of cell apoptosis pathway related protein in the damaged pancreas compared with the not-pretreated adipose-derived stem cells, wherein the group of cell apoptosis pathway related proteins comprises FADD, Caspase 8, Bax, Cytochrome C and Caspase 3, the percentage of decrease is 40%˜80%.

### Claim 11 (depends on 1)

The use of claim 1, characterized in that the pretreated adipose-derived stem cells reduce expression level of a fibrosis related protein in the damaged pancreas compared with the not-pretreated adipose-derived stem cells, wherein the fibrosis related protein is TGF-β, the percentage of decrease is 40%˜80%.
